The journal of contemporary dental practice · 2013
p53 as a neoplastic biomarker in patients with erosive and plaque like forms of oral lichen planus.
Сравнительное исследованиеСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Agha-Hosseini Farzaneh, Mirzaii-Dizgah Iraj
Аннотация
AIM: Unstimulated whole salivary p53 was assessed in patients suffering from erosive and plaque-like form of oral lichen planus (OLP).
MATERIALS AND METHODS: Eighteen patients with erosive form, 17 patients suffering from plaque-like form and 38 noninvolvement subjects were enrolled. The unstimulated whole saliva p53 level was assayed by ELISA.
RESULTS: The mean concentration of salivary p53 was significantly higher in patients with plaque-like form compared to both patients with erosive form and the control group.
CONCLUSION: We conclude that plaque like form of OLP is important in view of the potential for malignancy and is not safety form.
CLINICAL SIGNIFICANCE: It seems that all forms of OLP must be considered accurately, should be followed up with biannual examinations, and if possible, assessment of salivary p53 every year.
MATERIALS AND METHODS: Eighteen patients with erosive form, 17 patients suffering from plaque-like form and 38 noninvolvement subjects were enrolled. The unstimulated whole saliva p53 level was assayed by ELISA.
RESULTS: The mean concentration of salivary p53 was significantly higher in patients with plaque-like form compared to both patients with erosive form and the control group.
CONCLUSION: We conclude that plaque like form of OLP is important in view of the potential for malignancy and is not safety form.
CLINICAL SIGNIFICANCE: It seems that all forms of OLP must be considered accurately, should be followed up with biannual examinations, and if possible, assessment of salivary p53 every year.